Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis

By sjmartinez • May 1, 2024

Gu Y, Gebremariam T, Alkhazraji S, Youssef E, El-Gamal S, Matkovits T, Cobb J, Mannino R, Ibrahim AS. Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2024 Apr 30:e0154023. doi: 10.1128/aac.01540-23. Epub ahead of print. PMID: 38687015.

Tags: Amphotericin B, antifungal agents, Harbor UCLA, Infectious Diseases, lipid nanocrystal, liposomal amphotericin B, MAT2203, mucor, mucormycosis, murine, oral amphotericin B, Publications, Rhizopus

Clinical features, management, and outcomes of right heart thrombi: a retrospective cohort study

Fritzmann E, Yuen AD, Chang S, Yaqoob M, Kinninger A, Chung J, Vintch JRE, Matusov Y. Clinical features, management, and outcomes of right heart thrombi:[...]

Epigenetic Aging Clocks and Incident Cardiovascular Outcomes: Results From the MESA

Srivatsa S, Rice N, Pike JR, Smith JA, Ding J, Liu Y, Budoff M, Bey GS. Epigenetic Aging Clocks and Incident Cardiovascular Outcomes: Results From[...]

Low Prevalence of Coronary Artery Calcium in High Cardiometabolic Risk Kenyan Adults with and Without HIV: The ASANTE Study

Shah H, Krishnan S, Narashim A, Korir S, Omondi G, Maxime Ale B, Gitura BM, Kinuthia J, Farquhar C, Hsue PY, Budoff M, Longenecker CT,[...]